Chronic obstructive lung disease (COPD) and diffuse parenchymal lung diseases (DPLD),
including idiopathic pulmonary fibrosis (IPF) and sarcoidosis, are associated with a high …

Idiopathic pulmonary fibrosis (IPF) is a chronic and progressive disorder with an estimated
median survival time of 3–5 years after diagnosis. This condition occurs primarily in elderly …

Idiopathic pulmonary fibrosis (IPF) is a progressive, life-threatening, interstitial lung disease
of unknown etiology. The median survival of patients with IPF is only 2 to 3 years, yet some …

Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive, fibrosing interstitial pneumonia
of unknown aetiology. It is a rare disease, and its incidence and prevalence are not clear …

Idiopathic pulmonary fibrosis is a devastating, age-related lung disease of unknown cause
that has few treatment options. This disease was once thought to be a chronic inflammatory …

Pulmonary hypertension (PH) is a heterogeneous condition. To date, no registry data exists
reflecting the spectrum of disease across the five diagnostic groups encountered in a …

Patients with chronic lung diseases, particularly interstitial lung disease and chronic
obstructive pulmonary disease, frequently develop pulmonary hypertension, which results in …

Pulmonary hypertension remained an unexplained intractable disease with poor prognosis.
In the last 2 decades, however, the diagnosis and treatment methods for this disease …

Different anatomic and physiological changes occur in the lung of aging people that can
affect pulmonary functions, and different pulmonary diseases, including deadly diseases …

There is increasing clinical, radiologic, and pathologic recognition of the coexistence of
emphysema and pulmonary fibrosis in the same patient, resulting in a clinical syndrome …